Beckman Coulter received FDA clearance for their upgraded UniCel system, the DxH 800. This system offers improved sensitivity, specificity, and ease of use over the incumbant system.
Beckman Coulter, Inc. announced that based on current exchange rates, it expects fiscal 2008 revenue growth to be in the range of 12% to 13%, with a pretax profit growth of 10%. This is lowered from earlier estimates of 12%-14% revenue growth and 12%-15% pretax profit growth.